Medical/Pharmaceuticals
Anti-PD-1 monoclonal antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS was approved for marketing in China by NMPA
HANGZHOU, China, July 25, 2022 /PRNewswire/ -- Anti-PD-1 monoclonal antibody – PuyouhengTM (HX-008, pucotenlimab injection), was conditionally approved by the National Medical Products Administration (NMPA) for marketing inChina to treat patients with unresectable or metastatic microsatellite ins...
2022-07-25 18:47
2768
Fuzhou Rides on the Opportunity of "Digital China" to Make Its Name in the World
FUZHOU, China, July 25, 2022 /PRNewswire/ -- "Discover Fuzhou: The Digital China Summit", the themed promo film ofFuzhou City, Fujian Province, was shown on "China screen" at Times Square, New York on July 22. Riding on the opportunity of "Digital China",Fuzhou, a coastal city, is presenting its ...
2022-07-25 15:21
2913
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.The issue price is CNY 18...
2022-07-25 11:55
3792
4DMedical Lauds U.S. House of Representatives for Including Burn Pit Population Surveillance in FY 2023 Appropriations
Thousands of Impacted Veterans Will Benefit from Congressional Efforts LOS ANGELES, July 23, 2022 /PRNewswire/ -- 4DMedical, the leading developer of functional imaging software for respiratory illness, today praised the U.S. House of Representatives for including language calling on the Departme...
2022-07-23 00:59
5184
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada
SUZHOU, China and ROCKVILLE, MD, July 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma's novel...
2022-07-22 07:59
3079
AI-based Cancer Solution Pioneer Lunit Makes Market Debut
SEOUL, South Korea, July 21, 2022 /PRNewswire/ -- Lunit, a global provider of AI-powered cancer solutions, announced today that it made its stock market debut on the South Korean KOSDAQ under the ticker "A32813". Lunit's initial public offering of 1,215,800 shares of its common stock was priced a...
2022-07-21 21:00
2371
ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities
SHENZHEN, China, July 20, 2022 /PRNewswire/ -- ImmVira's global first intravenous ("IV") administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed the first three cohort escalation in the U.S. Phase I clinical trial, tested dosage from 1x106 to 1x108 PFU on 10 subjec...
2022-07-21 08:00
2314
Recruitment complete for Clarity's PROPELLER prostate cancer diagnostic trial
SYDNEY, July 20, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the completion of recruitment for the Phase I PROPELLER diagnosti...
2022-07-20 21:06
2240
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
* US Food and Drug Administration (FDA) fast-tracks idiopathic pulmonary fibrosis treatment DWN12088 * First-in-class new drug to quickly take on the pulmonary fibrosis market, predicted to reach$6.1 billion globally by 2030 SEOUL, South Korea, July 20, 2022 /PRNewswire/ -- As many Korean p...
2022-07-20 21:00
2287
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
SUZHOU, China, ROCKVILLE, Md. and SAN FRANCISCO, July 19, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01...
2022-07-20 00:15
2596
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of ...
2022-07-19 20:00
2441
China Pharma Announced the Submission of a Plan of Compliance to NYSE American
HAIKOU, China, July 18, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onJuly 15, 2022, the Company submitted a plan of compliance to NYSE American LLC ("NYSE American" or the...
2022-07-18 20:00
2406
OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002
SEOUL, South Korea, July 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to move forward to the second stage of the Phase 2a trial inAustralia in osteoarthritis (OA) patients for pain killer OLP-1002, an SCN9A...
2022-07-18 20:00
2140
Samsung Biologics to purchase land for its second Bio Campus
* Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 * Plans to build Multi-Modal Plant, Open Innovation, and expanded manufacturing capacities INCHEON, South Korea, July 18, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contrac...
2022-07-18 19:00
2364
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
Kinpeygo® (developed under the name NEFECON) is the first and only EMA- approved treatment for IgAN Everest Medicines has exclusive rights to develop and commercialize NEFECON in Greater China, Singapore and South Korea SHANGHAI, July 17, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Ev...
2022-07-18 08:00
2608
China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON
WUHAN, China and SAN DIEGO, July 15, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., ("Neurophth") today announced thatthe Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has granted a Breakthrough Therapy Designation (BTD) to the Company's leading gen...
2022-07-15 21:00
5788
Pulnovo Medical Concludes Successfully First Pre-Sub Meeting with FDA for PADN Global Clinical Trial
SHANGHAI, July 15, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in the treatment for cardiopulmonary diseases, today announced that it has successfully concluded the first Pre-Sub meeting with the U.S. Food and Drug Administration ("FDA") for its Pulmonary Ar...
2022-07-15 20:30
5358
Lunit to be Listed on KOSDAQ next week
* Initial Public Offering of 1,215,800 shares of its common stock at KRW 30,000 * To be listed on the KOSDAQ market on July 21, 2022 SEOUL, South Korea, July 14, 2022 /PRNewswire/ -- Lunit, a global provider of AI-based cancer solutions, announced that it priced its initial public offering (I...
2022-07-14 21:00
2692
Health2Sync and AstraZeneca Taiwan to Kick off Digital Patient Management Programs for Chronic Kidney Diseases
TAIPEI, July 13, 2022 /PRNewswire/ -- Health2Sync, Asia's leading digital chronic disease management platform, announced today that it is signing a Memorandum of Understanding (MOU) with AstraZeneca Taiwan to provide its first digital solution for chronic kidney disease (CKD) patients inTaiwan. T...
2022-07-13 12:47
2673
Bridge Biotherapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of BBT-176 at the World Conference of Lung Cancer
* The abstract suggests that BBT-176 has shown its capability of inducing clinical tumor responses in EGFR triple mutation-containing patients * Further exploration of the drug efficacy and safety profiles at RP2D is planned * The abstract is now available on the IASLC 2022 WCLC website SEON...
2022-07-13 06:30
2750
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 313 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
Most Read
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
12156
